Welcome to our dedicated page for Regen BioPharma SEC filings (Ticker: RGBPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Regen BioPharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Regen BioPharma's regulatory disclosures and financial reporting.
Regen BioPharma, Inc. disclosed that it raised cash through several unregistered sales of common stock to unaffiliated investors in mid-September 2025. On September 15, 2025 the company issued 3,320,000 common shares for cash consideration of $33,200, on September 16, 2025 it issued 1,000,000 shares for $10,000, and on September 18, 2025 it issued 1,500,000 shares for $15,000.
The shares were issued in reliance on Regulation A exemptions from registration under the Securities Act of 1933. No underwriters were involved, the sales were conducted directly by management without commissions or other consideration paid, and the company states that proceeds from each sale will be used for working capital.
Quick Capital, LLC reported beneficial ownership of 3,320,000 shares of Regen BioPharma, Inc. common stock, representing 9.9% of the outstanding class. The filing states Quick Capital has sole voting and sole dispositive power over all shares reported and identifies the filer as a Wyoming LLC with its business address in Miami, FL.
The statement is a passive Schedule 13G disclosure certifying the shares were not acquired to change or influence control of the issuer. No group affiliations, subsidiaries, or holdings on behalf of others are reported, and no shared voting or dispositive powers are disclosed.